Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an update.
Chimeric Therapeutics has reported a change to its capital structure with the expiry of 26,238 listed options, identified as CHMAY, on 30 April 2026. The options lapsed without being exercised, resulting in a modest reduction in the number of potential future shares, which marginally clarifies the company’s fully diluted share base for existing and prospective investors.
The cessation of these options does not alter the number of currently issued shares but slightly reduces potential dilution if the options had converted. This administrative update, disclosed via the ASX Appendix 3H notice, provides stakeholders with increased transparency around Chimeric Therapeutics’ outstanding securities and may support more precise valuation and capital management assessments.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is an Australian biotechnology company listed on the ASX under the ticker CHM. It operates in the life sciences sector, focusing on the development of therapeutic products, though this specific filing centers on its capital structure rather than its clinical or commercial programs.
Average Trading Volume: 220,497
Technical Sentiment Signal: Sell
Current Market Cap: A$7.29M
For an in-depth examination of CHM stock, go to TipRanks’ Overview page.